Bcl2-like protein 12 (BCL2L12)

Bcl2-like protein 12 (BCL2L12) is a member of the BCL-2 family of proteins that functions as a potent inhibitor of apoptosis and a key driver of treatment resistance in various malignancies, most notably glioblastoma multiforme (UniProt Q9HB09). Unlike many other BCL-2 family members that act primarily at the mitochondria, BCL2L12 exerts its anti-apoptotic effects by directly inhibiting effector caspases, such as Caspase-3 and Caspase-7, and by binding to the p53 tumor suppressor to neutralize its transcriptional activity and pro-apoptotic functions (Stegh et al., 2007, Genes & Development). In clinical contexts, BCL2L12 is frequently overexpressed in high-grade gliomas and is associated with poor prognosis and resistance to conventional chemotherapy and radiation (NCBI Gene ID: 83596). Therapeutic strategies targeting BCL2L12 have focused on the use of spherical nucleic acids (SNAs), such as the clinical candidate NU-0129, which are designed to cross the blood-brain barrier and trigger the degradation of BCL2L12 mRNA via RNA interference (Kumthekar et al., 2021, Science Translational Medicine). By reducing BCL2L12 levels, these therapies aim to sensitize tumor cells to apoptosis-inducing agents and improve patient outcomes in difficult-to-treat cancers.

Other names

Bcl-2-like protein 12BCL2L12Bcl2-L-12

RNA interference-mediated knockdown of BCL2L12 mRNA expression using spherical nucleic acids (SNAs) to restore apoptotic sensitivity in tumor cells.